$\Box$ 

FORM 4

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington,	D.C.	20549
-------------	------	-------

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

	OMB APPROVAL						
	OMB Number: 3235-0287						
l	Estimated average burden						
l	hours per response:	0.5					

D

	Check this box if no longer subject to
٦	Section 16. Form 4 or Form 5 obligations may continue. See
J	obligations may continue. See
	Instruction 1(b).

Date		2. Transaction Date (Month/Day/Year)	Execution Date,		iction Instr.	(A) or			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)	
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned												
(City)	(State)	(Zip)								1 013011		
SEATTLE	WA	98109							Form filed by More than One Reporting Person			
(Street)				·	Ü			,	Line)	Form filed by On	e Reporting Pers	ion
1165 EASTL	AKE AVENUE	E	4. If A	mendment, Date of 0	Original .	Filed	(Month/Dav/Ye	ar)	6. Indi	vidual or Joint/Grou	p Filing (Check A	pplicable
(Last)	(First)	(Middle)		3. Date of Earliest Transaction (Month/Day/Year) 01/26/2022				Officer (give title below)	Other below	(specify )		
1. Name and Address of Reporting Person* <u>Conroy Kevin T</u>				2. Issuer Name and Ticker or Trading Symbol Adaptive Biotechnologies Corp [ ADPT ]					S. Relationship of Reporting Person(s) to Issuer (Check all applicable)     X Director 10% Owner			
Instruction 1(t	o).			nt to Section 16(a) o ction 30(h) of the Inv					34	liouis	у рег тезропзе.	0.5

## Common Stock 01/26/2022 8,193 Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities) 3. Transaction 3A. Deemed Execution Date, 8. Price of Derivative 9. Number of derivative 11. Nature of Indirect 1. Title of 5. Number 6. Date Exercisable and 7. Title and Amount Conversion Transaction Ownership Derivative **Expiration Date** of Securities or Exercise Price of Derivative Derivative Underlying Derivative Security (Instr. 3 and 4) Securities Beneficially Owned Form: Direct (D) or Indirect Security (Instr. 3) (Month/Day/Year) if any (Month/Day/Year) Code (Instr. 8) (Month/Day/Year) Security (Instr. 5) Beneficial Securities Acquired (A) or Disposed Ownership (Instr. 4) (I) (Instr. 4) Security Following Reported Transaction(s) (Instr. 4) of (D) (Instr. 3, 4 and 5) Amount Number Date Exercisable Expiration Date oi Shares (D) Code (A) Stock Option Commo (1) \$14.95 01/26/2022 A 16,722 01/26/2032 16,722 \$0.00 16,722 D (Right to Buy)

6,689

## **Explanation of Responses:**

1. The option will vest in equal monthly installments over one year, subject to continued service as a director through such vesting date.

## Remarks:

/s/ Kevin Conroy by Eric Billings, attorney-in-fact

01/28/2022

\*\* Signature of Reporting Person

\$0.00

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- $^{\star}$  If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.